福元医药(601089) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 830,471,781.49, representing a year-on-year increase of 3.46% compared to CNY 802,722,388.57 in the same period last year[4]. - The net profit attributable to shareholders of the listed company was CNY 130,633,035.22, a decrease of 1.47% from CNY 132,577,291.60 in the previous year[4]. - The basic earnings per share for the period was CNY 0.27, down 3.57% from CNY 0.28 in the same period last year[4]. - Total operating revenue for Q1 2025 reached ¥830,471,781.49, an increase of 3.1% compared to ¥802,722,388.57 in Q1 2024[20]. - Net profit for Q1 2025 was ¥130,805,404.74, a decrease of 2.0% from ¥133,524,586.60 in Q1 2024[21]. - Basic earnings per share for Q1 2025 were ¥0.27, down from ¥0.28 in Q1 2024[22]. - The company reported a total comprehensive income of ¥130,805,404.74 for Q1 2025, slightly lower than ¥133,524,586.60 in Q1 2024[22]. Cash Flow and Investments - The net cash flow from operating activities decreased by 12.43%, amounting to CNY 125,998,539.47 compared to CNY 143,883,044.52 in the same period last year[4]. - Cash flow from operating activities for Q1 2025 was ¥125,998,539.47, compared to ¥143,883,044.52 in Q1 2024, reflecting a decrease of 12.4%[24]. - Cash inflow from investment activities in Q1 2025 totaled ¥2,424,339,329.07, significantly higher than ¥8,571,117.50 in Q1 2024[24]. - Net cash flow from investment activities for Q1 2025 was ¥202,128,392.81, recovering from a loss of ¥91,329,568.36 in Q1 2024[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,869,119,843.35, an increase of 1.09% from CNY 4,816,632,385.06 at the end of the previous year[5]. - As of March 31, 2025, the company's total assets amounted to RMB 4,869,119,843.35, an increase from RMB 4,816,632,385.06 as of December 31, 2024[15][17]. - The total current liabilities decreased to RMB 1,116,824,664.66 from RMB 1,189,939,548.36, a reduction of about 6.1%[18]. - The total non-current liabilities decreased to RMB 65,849,884.54 from RMB 70,611,449.20, a decline of about 6.6%[18]. - Total liabilities and shareholders' equity as of the end of Q1 2025 amounted to ¥4,869,119,843.35, compared to ¥4,816,632,385.06 at the end of Q1 2024[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,899[10]. - The company completed a share buyback of 12,000,000 shares, representing 2.5% of the total share capital, with an average repurchase price of RMB 14.68 per share[13]. - The company plans to repurchase shares for an amount ranging from RMB 100 million to RMB 200 million, with a maximum price of RMB 23.61 per share[12][13]. Equity and Retained Earnings - The equity attributable to shareholders of the listed company increased by 3.67%, reaching CNY 3,674,747,575.23 compared to CNY 3,544,556,038.10 at the end of the previous year[5]. - The company's retained earnings increased to RMB 1,505,945,270.24 from RMB 1,375,312,235.02, indicating a growth of approximately 9.4%[18]. - The company's total equity attributable to shareholders increased to RMB 3,674,747,575.23 from RMB 3,544,556,038.10, reflecting an increase of approximately 3.7%[18]. Inventory and Expenses - The company's inventory decreased to RMB 329,944,868.46 from RMB 347,555,462.41, reflecting a decline of approximately 5.0%[17]. - Research and development expenses for Q1 2025 were ¥74,193,792.66, a decrease of 8.9% from ¥80,972,978.85 in Q1 2024[20]. Other Financial Metrics - The weighted average return on net assets was 3.62%, a decrease of 0.12 percentage points from 3.74% in the previous year[5]. - The company reported a significant increase in investment income of 5,924.15%, primarily due to increased financial management income[7]. - The company experienced a 46.29% increase in prepayments, mainly due to increased procurement payments[7]. - The company reported a decrease in accounts payable from RMB 286,760,509.03 to RMB 266,994,507.71, a reduction of about 6.9%[18].